About Evotec
We are driven by a singular purpose, to be at the forefront of advancing medicine. As a leading drug discovery and development company, we combine cutting-edge science, innovative technologies, and strategic partnerships to accelerate the discovery and delivery of life-changing therapies. With an unwavering commitment to patients, our partners and customers, our multidisciplinary teams collaborate tirelessly to tackle the most pressing medical challenges, transforming scientific potential into tangible solutions.
Oligonucleotide Services
We specialize in providing comprehensive oligonucleotide services that span the entire discovery and development process for oligonucleotide therapeutics including design, synthesis, screening for potency and safety, off target effects, mechanism of action or proof of concept studies relevant to the disease biology, DMPK, tolerability and early safety, and GLP studies to support filing for First in Human.
Peptide Services
Evotec’s wide ranging expertise in disease biology including extensive in-vitro and in-vivo capabilities, combined with our peptide discovery enabling technologies, including state-of-the-art microwave-assisted solid phase peptide synthesis, can support your peptide drug discovery projects in this exponentially expanding field of applied research.
Our experience in peptide design and synthesis, via automated solid phase and hybrid solid/solution phase methodologies covers a large segment of the peptide chemical space; from simple linear and cyclized or stapled peptides through to mini proteins (beyond 60 amino acids), including the incorporation of non-natural and modified amino acids. Beyond the solid phase we have experience in the synthesis of more complex constructs ranging from polycyclic to multimeric peptides, including heteromers with potential for poly-pharmacology, in addition to conjugates of peptides with small molecules, bio-relevant macromolecules and half-life extension modifications.
Evotec also offers comprehensive DMPK expertise for peptides and peptide conjugates, including specialized assays for peptide stability, metabolite identification, and bioanalytical support. Our in vitro ADME assays are adapted to address challenges like non-specific binding, rapid enzymatic degradation, and poor stability. This includes advanced permeability assays, with and without permeation enhancers, crucial for developing orally bioavailable peptides. These in vitro assays are complemented by in vivo pharmacokinetic models, like intraduodenal dosing, to understand peptide oral absorption comprehensively. Additionally, Evotec provides peptide formulation strategies to enhance stability and bioavailability.
Modeling and simulation capabilities further support peptide development by predicting human pharmacokinetics (PK) and optimal dosing, using techniques like physiologically based pharmacokinetic (PBPK) modeling to predict peptide behavior in the body.
